https://www.selleckchem.com/products/dcemm1.html 3%. There were 37 discordant samples including 30 with BD RPR+/BioPlex RPR- and 7 with BD RPR-/BioPlex RPR+. Negative BioPlex RPR results were observed in samples with reactive BD RPR 10 out of 11 (91%) for BD RPR 11, 13 out of 20 (65%) for BD RPR 12, 6 out of 17 (35%) for BD RPR 14 and 1 out of 14 (7%) for BD RPR 18. The discordant samples were predominantly from patients with high-risk of syphilis reinfection and included nine patients with an early reinfection. CONCLUSIONS Our results demonstrated that BioPlex Syphilis Total and Architect Syphilis TP performed similarly. The BioPlex RPR missed a small number of early syphilis reinfections and its implementation should depend on the patient population that the laboratory serves.We report on the first high-level azithromycin resistant Neisseria gonorrhoeae isolate (MIC ≥ 256 μg/ml) in North Carolina isolated from a pharyngeal swab of a 33-year-old HIV-negative man who has sex with men. In addition, the isolate was found to be susceptible to cefixime, ceftriaxone, and penicillin and resistant to tetracycline. By whole genome sequencing, the strain was assigned as MLST ST9363, NG-MAST ST5035 and a novel NG-STAR sequence type, ST1993.BACKGROUND Rectal Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) are increasingly recognized as common infections among women. Little is known about the prevalence of rectal Mycoplasma genitalium (MG), rectal MG/CT/GC co-infection, or MG antimicrobial resistance patterns among women. METHODS In 2017-2018 we recruited women at high risk for CT from Seattle's municipal STD clinic. Participants self-collected vaginal and rectal specimens for CT/GC nucleic acid amplification testing (NAAT). We retrospectively tested samples for vaginal and rectal MG using NAAT, and tested MG-positive specimens for macrolide resistance-mediating mutations (MRM) and ParC quinolone resistance-associated mutations (QRAMs). RESULTS Of 50 enrolled women, 1